Micro,
Год журнала:
2023,
Номер
3(3), С. 749 - 762
Опубликована: Сен. 21, 2023
Plateaus
in
the
efficacy
of
traditional
methods
for
treatment
cancer
reached
last
decades
call
exploration
alternative
models
as
their
potential
clinical
complements.
Here,
classical
view
a
tissue
that
is
to
be
eradicated
by
describable
compendium
militaristic
metaphors
being
challenged
with
provocative
idea:
what
if
can
cured
love
condensed
down
level
molecular
and
cell
biology?
Correspondingly,
idea
mimics
traits
objects
its
affection
helps
them
grow
was
translated
biology
incorporating
anti-apoptotic
properties
healthy
cells
promoting
tumorigenesis
cancerous
cells.
Both
indirect
direct
co-culture
two
types
demonstrated
hindered
growth
relative
primary
counterparts
when
these
cellular
modifications
inspired
were
implemented.
The
experimental
reported
here
are
emphasized
crude
simplistic
derived
from
may
best
treated
loved
at
levels.
More
comprehensive
effective
emanate
continued
expansion
intriguing
innovative
avenue
management
proposed
here.
Journal of Biomedical Science,
Год журнала:
2024,
Номер
31(1)
Опубликована: Фев. 17, 2024
Abstract
Translational
research
plays
a
key
role
in
drug
development
and
biomarker
discovery
for
hepatocellular
carcinoma
(HCC).
However,
unique
challenges
exist
this
field
because
of
the
limited
availability
human
tumor
samples
from
surgery,
lack
homogenous
oncogenic
driver
mutations,
paucity
adequate
experimental
models.
In
review,
we
provide
insights
into
these
review
recent
advancements,
with
particular
focus
on
two
main
agents
currently
used
as
mainstream
therapies
HCC:
anti-angiogenic
immunotherapy.
First,
examine
pre-clinical
clinical
studies
to
highlight
determining
optimal
therapeutic
combinations
biologically
effective
dosage
HCC.
Second,
discuss
focusing
anti-PD1/anti-PD-L1-based
combination
therapy.
Finally,
progress
made
our
collective
understanding
immunology
multi-omics
analysis
technology,
which
enhance
mechanisms
underlying
immunotherapy,
characterize
different
patient
subgroups,
facilitate
novel
approaches
improve
treatment
efficacy.
summary,
provides
comprehensive
overview
efforts
translational
aiming
at
advancing
improving
Pharmaceutics,
Год журнала:
2024,
Номер
16(2), С. 179 - 179
Опубликована: Янв. 26, 2024
Solid
tumors
are
composed
of
a
highly
complex
and
heterogenic
microenvironment,
with
increasing
metabolic
status.
This
environment
plays
crucial
role
in
the
clinical
therapeutic
outcome
conventional
treatments
innovative
antitumor
nanomedicines.
Scientists
have
devoted
great
efforts
to
conquering
challenges
tumor
microenvironment
(TME),
respect
effective
drug
accumulation
activity
at
site.
The
main
focus
is
overcome
obstacles
abnormal
vasculature,
dense
stroma,
extracellular
matrix,
hypoxia,
pH
gradient
acidosis.
In
this
endeavor,
nanomedicines
that
targeting
distinct
features
TME
flourished;
these
aim
increase
site
specificity
achieve
deep
penetration.
Recently,
research
focused
on
immune
reprograming
order
promote
suppression
cancer
stem
cells
prevention
metastasis.
Thereby,
several
nanomedicine
therapeutics
which
shown
promise
preclinical
studies
entered
trials
or
already
practice.
Various
novel
strategies
were
employed
trials.
Among
them,
based
biomaterials
show
improving
efficacy,
reducing
side
effects,
promoting
synergistic
for
responsive
targeting.
review,
we
mechanisms
response
solid
tumors.
We
describe
take
advantage
biomaterials’
properties
exploit
posed
by
TME.
development
such
systems
has
significantly
advanced
application
combinational
therapies
immunotherapies
improved
anticancer
effectiveness.
Diagnostics,
Год журнала:
2023,
Номер
13(6), С. 1169 - 1169
Опубликована: Март 18, 2023
Epithelial
ovarian
cancer
is
by
far
the
most
lethal
gynecological
malignancy.
The
exploration
of
promising
immunomarkers
to
predict
prognosis
in
patients
remains
challenging.
In
our
research,
we
carried
out
an
integrated
bioinformatic
analysis
genome
expressions
and
their
immune
characteristics
microenvironment
with
validation
different
experiments.
We
filtrated
332
differentially
expressed
genes
10
upregulated
hub
from
Gene
Expression
Omnibus
database.
These
were
closely
related
tumorigenesis.
Subsequently,
survival
infiltration
demonstrated
that
upregulation
five
candidate
genes,
ITGB2,
VEGFA,
CLDN4,
OCLN,
SPP1,
correlated
unfavorable
clinical
outcome
increased
cell
cancer.
Of
these
ITGB2
tended
be
gene
various
infiltrations
had
a
strong
correlation
significant
M2
macrophages
(r
=
0.707,
p
4.71
×
10−39),
while
it
moderate
CD4+/CD8+
T
cells
B
cells.
This
characteristic
explains
why
high
expression
was
accompanied
activation
but
did
not
reverse
carcinogenesis.
Additionally,
confirmed
over-expressed
tissues
mainly
located
cytoplasm,
detected
Western
blotting
immunohistochemical
method.
summary,
may
serve
as
prognostic
immunomarker
for
patients.
Journal of Cellular and Molecular Medicine,
Год журнала:
2025,
Номер
29(6)
Опубликована: Март 1, 2025
Triple-negative
breast
cancer
(TNBC)
poses
a
significant
challenge
due
to
its
high
mortality
rates,
primarily
attributed
resistance
against
chemotherapy
regimens
containing
taxanes
like
paclitaxel.
Thus,
developing
combinatorial
strategies
override
is
pressing
need.
By
taking
advantage
of
library
screening
with
various
kinase
inhibitors,
we
found
that
the
small-molecule
inhibitor
enzastaurin
targeting
protein
C
(PKC)
could
overcome
in
TNBC
cells.
Mechanistically,
dual
treatment
paclitaxel
and
resulted
efficient
mitotic
arrest
subsequent
cell
death
by
restoring
AURKB
expression.
Further
analysis
revealed
GCN2-p-eIF2α
axis
was
responsible
for
posttranscriptional
accumulation
upon
treatment.
Finally,
confirmed
synergistically
suppressed
tumour
growth
vivo
mouse
models.
Moreover,
efficiency
largely
determined
AURKB,
implying
be
potential
predictive
marker
stratifying
patients
who
may
benefit
from
Collectively,
our
study
not
only
unravels
novel
underlying
mechanism
but
also
provides
new
therapeutic
strategy
clinic.
